With DxS, Qiagen Moves into Personalized Medicine

By Mark L. Ratner, IN VIVO 10/1/2009

• Around the Industry
• Word Count: 767
• Art # 2009800176

Executive Summary

IN VIVO -- Qiagen has bought up DxS, a private UK-based provider of molecular tests including one for the mutant oncogene KRAS. Like the June 2009 deal by Labcorp. for Monogram Biosciences, it shows how IVD companies with very different business models are moving towards a common ground in personalized medicine and disease management.

For $35, purchase this 767-word article as a PDF, and receive immediate delivery via email. View a complete sample article.
Questions? Call Toll Free (800) 332-2181 or (908) 547-2159.

100% Satisfaction Guarantee